Signing its first deal in Asia, Atomwise has agreed to partner with Hansoh Pharmaceutical to design and discover drug candidates for 11 undisclosed target proteins for multiple disease areas using Atomwise’s artificial intelligence technology. The deal, worth up to a potential US$1.5 B, combines Atomwise’s small protein structure expertise with Hansoh’s large-scale manufacturing and commercial capabilities. The deal comes just months after Hansoh completed its US$1 B IPO.